Journal article icon

Journal article

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis

Abstract:

Obeticholic acid (OCA), a potent farnesoid X receptor agonist, was studied as monotherapy in an international, randomized, double‐blind, placebo‐controlled phase 2 study in patients with primary biliary cholangitis who were then followed for up to 6 years. The goals of the study were to assess the benefit of OCA in the absence of ursodeoxycholic acid, which is relevant for patients who are intolerant of ursodeoxycholic acid and at higher risk of disease progression. Patients were randomized a...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Publisher copy:
10.1002/hep.29569

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Role:
Author
Publisher:
Wiley
Journal:
Hepatology More from this journal
Volume:
67
Issue:
5
Pages:
1890-1902
Publication date:
2018-01-29
Acceptance date:
2017-09-27
DOI:
EISSN:
1527-3350
ISSN:
0270-9139
Pmid:
29023915
Language:
English
Keywords:
Pubs id:
pubs:737220
UUID:
uuid:d0622472-10ca-4006-b30c-998e22acc8d7
Local pid:
pubs:737220
Source identifiers:
737220
Deposit date:
2019-01-30

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP